Perhaps because it’s looking like Trump may be trying to manufacture a recession – or at least a weaker U.S. dollar – EZZ Life Sciences (ASX:EZZ) fell -5% in early trades on Tuesday as the company flagged a strategic push to manufacture in the United States.

The company is teaming up with another called GLSP and the latter will manufacture EZZ’s products in the U.S. – namely, nutrition supplements.

EZZ has tasked GLSP with complying with overhead FDA manufacturing rules and other international standards, including third party laboratory testing of endproducts.

“This agreement represents a pivotal step in our global expansion strategy. By manufacturing in the United States, we enhance our ability to serve customers in North America with greater speed and efficiency,” EZZ Chair Glenn Cross said.

This will be EZZ’s first foray into America, but it’s done so at a precarious time.

The ASX sunk further on Tuesday as Trump’s tariff strategy hasn’t passed the pub test on Wall Street. The FDA is also under the direction of anti-vaxxer Robert F Kennedy – his true influence is still somewhat unclear.

EZZ last traded at $1.61/sh.

Join the discussion: See what HotCopper users are saying about EZZ Life Sciences and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.